World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
120
Citations
63622
World Ranking
3698
National Ranking
2037

Overview

Robert A. Figlin is affiliated with Cedars-Sinai Medical Center in the United States and has contributed extensively to the fields of medicine and biochemistry, genetics, and molecular biology. Their research primarily focuses on oncology, pulmonary and respiratory medicine, molecular biology, cancer research, and economic and financial impacts of cancer.

Their work spans multiple main topics, including:

  • Renal cell carcinoma treatment
  • Renal and related cancers
  • Cancer genomics and diagnostics
  • Cancer immunotherapy and biomarkers
  • Prostate cancer treatment and research
  • Pancreatic and hepatic oncology research
  • Economic and financial impacts of cancer

Recent impactful papers authored or coauthored by Robert A. Figlin include:

  • "Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma," 2023, Journal of Clinical Oncology
  • "Efficacy and Safety of Telaglenastat Plus Cabozantinib vs Placebo Plus Cabozantinib in Patients With Advanced Renal Cell Carcinoma," 2022, JAMA Oncology
  • "Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study," 2023, The Lancet Oncology
  • "COVID-19 and androgen-targeted therapy for prostate cancer patients," 2020, Endocrine Related Cancer
  • "Results of the ADAPT Phase 3 Study of Rocapuldencel-T in Combination with Sunitinib as First-Line Therapy in Patients with Metastatic Renal Cell Carcinoma," 2020, Clinical Cancer Research

Frequent coauthors collaborating with Robert A. Figlin include William J. Gradishar, New York, Tanios Bekaii-Saab, Eric J. Sherman, and Malignancies Landgren.

Their publications appear predominantly in venues such as:

  • ONCOLOGY
  • Journal of Clinical Oncology
  • Kidney Cancer Journal
  • The Lancet Oncology
  • OncoTargets and Therapy

Best Publications

  • Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

    Gary Hudes;Michael Carducci;Piotr Tomczak;Janice Dutcher

  • Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;Thomas E. Hutson;Piotr Tomczak;M. Dror Michaelson

  • Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma

    Robert J. Motzer;M. Dror Michaelson;Bruce G. Redman;Gary R. Hudes

  • Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

    Robert J. Motzer;Bernard Escudier;Stephane Oudard;Thomas E. Hutson

  • Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease.

    Nicolette K Janzen;Hyung L Kim;Robert A Figlin;Arie S Belldegrun

  • Improved Prognostication of Renal Cell Carcinoma Using an Integrated Staging System

    Amnon Zisman;Allan J. Pantuck;Fredrick Dorey;Jonathan W. Said

  • Prognostic Value of Histologic Subtypes in Renal Cell Carcinoma: A Multicenter Experience

    Jean Jacques Patard;Emmanuelle Leray;Nathalie Rioux-Leclercq;Luca Cindolo

  • Risk Group Assessment and Clinical Outcome Algorithm to Predict the Natural History of Patients With Surgically Resected Renal Cell Carcinoma

    Amnon Zisman;Allan J. Pantuck;Jeffery Wieder;Debby H. Chao

  • Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: Implications for prognosis and therapy

    Matthew H.T. Bui;David Seligson;Ken ryu Han;Allan J. Pantuck

  • SAFETY AND EFFICACY OF PARTIAL NEPHRECTOMY FOR ALL T1 TUMORS BASED ON AN INTERNATIONAL MULTICENTER EXPERIENCE

    Jean-Jacques Patard;Oleg Shvarts;John S. Lam;Allan J. Pantuck

  • Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells

    Hong Xin;Chunyan Zhang;Andreas Herrmann;Yan Du

  • Hypertension as a Biomarker of Efficacy in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib

    Brian I. Rini;Darrel P. Cohen;Dongrui R. Lu;Isan Chen

  • Carbonic Anhydrase IX Is an Independent Predictor of Survival in Advanced Renal Clear Cell Carcinoma

    Matthew H. T. Bui;David Seligson;Ken-ryu Han;Allan J. Pantuck

  • NCCN clinical practice guidelines in oncology: kidney cancer.

    Robert J Motzer;Neeraj Agarwal;Clair Beard;Graeme B Bolger

  • Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria.

    Ke-Hung Tsui;Oleg Shvarts;Robert B. Smith;Robert A. Figlin

  • Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.

    John S. Lam;Oleg Shvarts;John T. Leppert;Robert A. Figlin

  • Use of the University of California Los Angeles Integrated Staging System to Predict Survival in Renal Cell Carcinoma: An International Multicenter Study

    Jean Jacques Patard;Hyung L. Kim;John S. Lam;Frederick J. Dorey

  • An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial

    Christopher Wood;Pramod Srivastava;Ronald Bukowski;Louis Lacombe

  • RENAL CELL CARCINOMA: PROGNOSTIC SIGNIFICANCE OF INCIDENTALLY DETECTED TUMORS

    Ke-Hung Tsui;Oleg Shvarts;Robert B. Smith;Robert Figlin

Frequent Co-Authors

Arie S. Belldegrun
Arie S. Belldegrun University of California, Los Angeles
Allan J. Pantuck
Allan J. Pantuck University of California, Los Angeles
Robert J. Motzer
Robert J. Motzer Memorial Sloan Kettering Cancer Center
Thomas E. Hutson
Thomas E. Hutson Texas Oncology
Christopher G. Wood
Christopher G. Wood The University of Texas MD Anderson Cancer Center
Jonathan W. Said
Jonathan W. Said University of California, Los Angeles
Frederick J. Dorey
Frederick J. Dorey University of California, Los Angeles
Brian I. Rini
Brian I. Rini Vanderbilt University Medical Center
Ronald M. Bukowski
Ronald M. Bukowski Cleveland Clinic
Hua Yu
Hua Yu City Of Hope National Medical Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you're interested in healthcare careers beyond traditional Medicine, there are several flexible online degrees to explore. These online programs make it possible to start or advance your healthcare career from anywhere in the USA.

For registered nurses seeking to further their education, the cheapest online bsn programs offer affordable pathways to a Bachelor of Science in Nursing. If you want to pivot into nursing from a different field, direct msn programs online are designed for non-nursing graduates who are ready to transition quickly.

Those just starting out can consider online adn programs that provide streamlined entry into the nursing profession. Meanwhile, careers like medical billing and coding are experiencing rapid growth and can be started via an accredited certificate or degree. Interested in this pathway? Discover programs that offer online medical billing and coding with financial aid.

These online options help make healthcare education more accessible, providing a variety of career paths for future professionals.

Best Scientists Citing Robert A. Figlin

Trending Scientists